ECULIZUMAB (SOLIRIS®) PRESCRIBER ORDER FORM						
Patient Name:		Date of Birth:		Gender:	Gender:	
Address:		•				
Phone:		Height:	\square inches \square cm	Weight:	☐ Ibs ☐ kg	
Clinical Information						
Primary Diagnosis Description:	s completed – date:					
Meningococcal Vaccination Status:	☐ MenACWY booster comple					
☐ MenB booster completed – date:						
Eculizumab (Soliris®) Prescription Eculizumab (Soliris®) refill as directed x 1 year Induction Dose:						
☐ Other: Max infusion time not to exceed 2 hours.						
Anaphylaxis Kit If this is a first dose, does this patient require an anaphylaxis kit? Yes, with 1st dose Yes, with all doses						
Lab Orders No labs ordered at this time Other: Skilled nurse to assess and administer provide ongoing support as needed. If patient is seen within a provider led treatment, and IV flush administration I certify that the use of the Prescriber Signature:	and/or teach self-administrati Refill above ancillary orders as infusion clinic, Option Care He will be followed per provider the indicated treatment is medic	directed x 1 year. Falth's infusion reaction oversight. No indivice tally necessary, and its second	ion management po dual anaphylaxis kit will be supervising	olicy, skilled nursin will be dispensed.	g plan of	
Prescriber Name:	per Information Phone:					
Address:		NPI:				
City, State: Zip:		Office Contact:				
Σ.γ.		Office Contact.				

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.